Boston Scientific wins Chinese nod for asthma treatment device; Device tax fight marches on;

@FierceMedDev: UPDATED: Boston Scientific to slash up to 1,500 more jobs even as Q3 numbers improve. Story | Follow @FierceMedDev

@MarkHFierce: Check out this week's FierceDiagnostics newsletter | Follow @MarkHFierce

@MichaelGFierce: Layered nanoparticles deliver RNA, chemo for one-two punch. Item from FierceDrugDelivery | Follow @MichaelGFierce

> Boston Scientific ($BSX) has won Chinese FDA approval for its Alair bronchial thermoplasty system, designed to treat severe asthma not controlled by drugs. News

> Hospira ($HSP) has launched its Sapphire infusion pump in the U.S., moving on from the troubled devices it has since pulled from the market. More

> A repeal of the medical device tax didn't find its way into this month's debt ceiling agreement, but the industry and its lobbyists are far from resigned to failure. Article

> Invacare ($IVC) is still working its way out from under an FDA consent decree that has marred its manufacturing capabilities, planning to submit its final audit report to the agency next month. Item

> Toumaz won a CE mark approval for a product designed to transfer patients' vital signs wirelessly to clinicians by way of a web-enabled device. Story

> Nonin Medical obtained FDA clearance for its new Bluetooth Smart Model 3230 finger pulse oximeter. Item

> PTV Sciences, an Austin-based venture capital firm that focuses, in part, on medical devices, raised $24.7 million for a new fund. Story

Biotech News

@FierceBiotech: ICYMI yesterday: The top 10 biotech IPOs of 2013. Special report | Follow @FierceBiotech

@JohnCFierce: Rigel sinks after adding another trial failure to its losing streak. News | Follow @JohnCFierce

@DamianFierce: Repros tanks as FDA scrutiny of testosterone drug pushes back NDA date. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: ICYMI: Takeda, Hopkins developing new pancreatic cancer drugs. More from FierceBiotech Research | Follow @EmilyMFierce

> Armed-antibody successes inspire a burst of new building projects, industry deals. More

> Troubled Merck shrugs off fresh doubts about late-stage heart drug. Article

> Bristol-Myers exec sentenced to a year in prison on insider trading scheme. Report

> AstraZeneca plans to shutter lab, ax staffers. Item

Pharma News

@FiercePharma: Roche is putting $900M into biologics manufacturing, but turning to Samsung for some of its drugs. News | Follow @FiercePharma

@CarlyHFierce: Here's FiercePharmaManufacturing's take on McKesson's Celesio buyout. More | Follow @CarlyHFierce

> GlaxoSmithKline saves $431M moving retirees to private healthcare exchanges. Article

> Teva ex-chairman: Execs should share layoffs pain with 10% pay cut. Story

Pharma Manufacturing News

@EricPFierce: Samsung, which has worked on a biosimilar of Rituxan, has a new deal to make biologics for Roche. Article | Follow @EricPFierce

> Stolen Novo growth hormone sold on Internet. Item

> McKesson makes $8.3B move on Europe. Story

> Actis invests $48M in API maker Symbiotec. News

> Hospira unveils new quality lab at troubled plant. More

Vaccines News

> Finnish team talks up prospects of Type 1 diabetes vaccine. Report

> Study finds herd immunity protects babies against whooping cough. More

> Meta-analysis links flu vaccine to lower risk of heart attack and stroke. Article

> Timing of first measles vaccine dose linked to effectiveness. Item

> Taliban anti-vaccine push raises risk of polio outbreak. Story

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.